Clinical Trials Logo

Advanced Prostate Cancer clinical trials

View clinical trials related to Advanced Prostate Cancer.

Filter by:

NCT ID: NCT02420977 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Start date: December 6, 2018
Phase: Early Phase 1
Study type: Interventional

This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.

NCT ID: NCT02362620 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.

PROSTAC
Start date: May 2014
Phase:
Study type: Observational

PROSTAC is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with docetaxel or cabazitaxel

NCT ID: NCT02234089 Completed - Clinical trials for Advanced Prostate Cancer

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.

ProComD
Start date: September 2014
Phase:
Study type: Observational

The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen deprivation therapy (Degarelix or LHRH agonists).

NCT ID: NCT02035124 Withdrawn - Clinical trials for Advanced Prostate Cancer

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Start date: April 2014
Phase: Phase 2
Study type: Interventional

Although there have been advances in the treatment of patients with metastatic castrate-resistant prostate cancer (mCRPC), all patients eventually develop resistance to available therapy. Docetaxel is the accepted first-line agent followed by cabazitaxel in the post-docetaxel phase. In this study the investigators propose to evaluate BKM120, a PI3K inhibitor, with cabazitaxel in the treatment of patients with advanced prostate cancer.

NCT ID: NCT01383863 Completed - Clinical trials for Advanced Prostate Cancer

A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer

TRIPTOCARE LT
Start date: October 2011
Phase:
Study type: Observational

The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with advanced disease.

NCT ID: NCT01306890 Completed - Prostatic Neoplasms Clinical Trials

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

PROCEED
Start date: January 27, 2011
Phase:
Study type: Observational

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

NCT ID: NCT01224405 Active, not recruiting - Clinical trials for Advanced Prostate Cancer

Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy

PON-PC-02
Start date: April 2010
Phase: Phase 3
Study type: Interventional

The study includes the recruitment of patients with advanced prostate cancer resistant to chemical castration This is a multicenter prospective trial randomized phase III

NCT ID: NCT01078545 Completed - Clinical trials for Lower Urinary Tract Symptoms

Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)

LEMON
Start date: September 2008
Phase: N/A
Study type: Observational

The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms (LUTS) in patients with diagnosed locally advanced and/or metastatic prostate cancer and LUTS.

NCT ID: NCT00871585 Completed - Clinical trials for Advanced Prostate Cancer

Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

Start date: March 2009
Phase: N/A
Study type: Observational

Prospective, non-comparative, non-interventional, observational study to collect and analyse real life environment data on advanced prostate cancer patients receiving combination treatment of medical or surgical castration and bicalutamide according to routine medical practice in Croatia. The main aim is to evaluate change of PSA level and prescribing practices based on prostate cancer stage.